Precision Medicine Execution: Accelerating Diagnostic Impact

Ken Ruppel is the Vice President of Scientific and Medical Services at Diaceutics, where he plays a pivotal role in driving innovation and supporting global leaders in the development of impactful commercialization strategies for the launch of precision medicines. With over 25 years of experience in the medical research, life sciences, pharmaceutical, biotechnology and clinical diagnostic markets, Ken brings a wealth of expertise and strategic vision to Diaceutics.

Before joining Diaceutics, Ken served as the VP of Precision Medicine at Amplity Health, where he has supported the strategy and execution of 20+ companion diagnostic indications in the last six years. At Diaceutics, Ken leverages his extensive background to foster innovation and ensure that precision medicine strategies are effectively operationalized.

His commitment to advancing precision medicine is evident in his collaborative approach, working closely with pathologists and other key stakeholders to create academic-level care in the community.

Dishant Kalra leads the Precision Medicine practice at Astellas Pharma, where he is responsible for shaping the strategic vision and execution of biomarker strategy, diagnostics co‑development, and personalized health solutions. In his role, Dishant works at the intersection of translational science, clinical development, and commercial diagnostics, guiding efforts to identify, validate, and implement biomarkers that enable more targeted therapeutic approaches, enhanced patient stratification, and optimized treatment outcomes. He is a recognized voice in the precision medicine field, invited to share his expertise at international events.

He has engaged in key discussions around artificial intelligence, data, and how to overcome barriers to implementing personalized medicine.